Sofinnova Investments, a biopharmaceutical investment firm, announced today the addition of Maha Radhakrishnan, M.D. to the investment team as an Executive Partner. Dr. Radhakrishnan is an accomplished industry executive with over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies.
